SCHEDULE: Millennium Management Discloses Stake in Avalo Therapeutics

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has filed a Schedule 13G, reporting beneficial ownership of Avalo Therapeutics, Inc. common stock.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, indicating their beneficial ownership of Avalo Therapeutics, Inc. common stock.
• The filing reports a total of 9,857 shares beneficially owned, representing 0.0% of the class of securities.
• Millennium Management LLC is identified as the primary reporting entity, with shared voting and dispositive power held by the reporting persons.
• The filing is an amendment, indicating a change or update to previous filings.
• The date of the event requiring this filing is June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the minimal reported ownership percentage (0.0%), which suggests a lack of significant investment or influence.

Positives

• The filing confirms a reporting entity's stake in Avalo Therapeutics, Inc., providing transparency to the market.
• The joint filing agreement ensures coordinated reporting among affiliated entities and individuals.

Negatives

• The reported beneficial ownership is a very small percentage (0.0%) of the total class of securities, suggesting a minimal direct influence on the company.
• The filing does not provide details on the acquisition cost or strategy behind holding these shares.

Risks

• The minimal ownership percentage (0.0%) could indicate a lack of significant conviction or influence over Avalo Therapeutics, Inc.'s strategic direction.
• As a Schedule 13G filing, it pertains to passive investors, meaning these entities are not actively seeking to control or influence the issuer.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding future performance or strategy for Avalo Therapeutics, Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. However, in this instance, the reported ownership is 0.0%, which is unusual for a 13G filing and may indicate a de minimis holding or a reporting adjustment.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant investment management firm's holdings, though the minimal percentage may not significantly impact market perception.

Next Steps

• Continue to monitor future SEC filings from Millennium Management LLC and Avalo Therapeutics, Inc. for any changes in ownership or strategic developments.

Key Dates

Keywords

Avalo Therapeutics, Millennium Management, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Securities Exchange Act